Capital Investment Advisory Services’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$350K Sell
1,845
-72
-4% -$13.5K 0.02% 536
2026
Q1
$378K Buy
1,917
+56
+3% +$10.8K 0.03% 457
2025
Q4
$342K Buy
1,861
+138
+8% +$24.2K 0.02% 469
2025
Q3
$264K Buy
1,723
+38
+2% +$5.75K 0.02% 507
2025
Q2
$236K Sell
1,685
-172
-9% -$24.1K 0.02% 515
2025
Q1
$273K Buy
1,857
+196
+12% +$28.4K 0.02% 460
2024
Q4
$218K Sell
1,661
-603
-27% -$84.4K 0.02% 472
2024
Q3
$353K Sell
2,264
-9
-0.4% -$1.45K 0.03% 377
2024
Q2
$354K Buy
2,273
+25
+1% +$3.76K 0.04% 357
2024
Q1
$305K Sell
2,248
-566
-20% -$74.9K 0.03% 398
2023
Q4
$379K Sell
2,814
-688
-20% -$89.4K 0.04% 356
2023
Q3
$474K Buy
3,502
+707
+25% +$96.6K 0.05% 287
2023
Q2
$400K Sell
2,795
-171
-6% -$25.2K 0.04% 313
2023
Q1
$412K Sell
2,966
-195
-6% -$26.2K 0.05% 297
2022
Q4
$429K Sell
3,161
-597
-16% -$74.9K 0.05% 300
2022
Q3
$412K Sell
3,758
-95
-2% -$12.1K 0.05% 286
2022
Q2
$509K Buy
3,853
+169
+5% +$22.2K 0.06% 257
2022
Q1
$489K Sell
3,684
-524
-12% -$62.8K 0.05% 287
2021
Q4
$490K Sell
4,208
-142
-3% -$16.7K 0.06% 276
2021
Q3
$522K Sell
4,350
-3,504
-45% -$408K 0.07% 256
2021
Q2
$941K Sell
7,854
-2,547
-24% -$279K 0.12% 170
2021
Q1
$1.03M Sell
10,401
-3,751
-27% -$377K 0.15% 143
2020
Q4
$1.42M Sell
14,152
-12
-0.1% -$1.27K 0.21% 106
2020
Q3
$1.55M Buy
14,164
+50
+0.4% +$5.56K 0.29% 81
2020
Q2
$1.49M Buy
14,114
+46
+0.3% +$4.75K 0.3% 79
2020
Q1
$1.26M Buy
+14,068
New +$1.32M 0.31% 72
2019
Q4
Sell
-1,420
Closed -$127K 602
2019
Q3
$127K Buy
1,420
+70
+5% +$6.07K 0.04% 339
2019
Q2
$109K Buy
1,350
+250
+23% +$19.6K 0.03% 368
2019
Q1
$89K Hold
1,100
0.03% 365
2018
Q4
$84K Buy
+1,100
New +$85.9K 0.04% 341

Other funds holding AZN

Capital Investment Advisory Services's AZN Position: Q2 2026 in Review

Capital Investment Advisory Services reduced its AstraZeneca (AZN) stake by 3.8% in Q2 2026, selling an estimated $13.5K and leaving 1,845 shares worth $350K. The position accounts for 0.02% of the portfolio, ranked #536.

Capital Investment Advisory Services first reported a position in AZN in Q4 2018 and has held it in 30 quarters since. The position peaked at $1.55M in Q3 2020. 452 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Capital Investment Advisory Services held 1,845 shares of AstraZeneca worth $350K as of Q2 2026.
  • Capital Investment Advisory Services sold 72 AstraZeneca shares in Q2 2026, an estimated $13.5K.
  • AstraZeneca made up 0.02% of Capital Investment Advisory Services's portfolio in Q2 2026, its #536 holding.
  • Capital Investment Advisory Services first reported a position in AstraZeneca in Q4 2018 and has held it in 30 quarters since.
  • Capital Investment Advisory Services's AstraZeneca position peaked at $1.55M in Q3 2020.
  • 452 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.